Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | terminated | Phase 2 | 6 | University of Alabama at BirminghamOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-01) | terminated | Phase 1 / Phase 2 | 13 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 |
| clinicaltrials |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 2 | 34 | Translational Research in OncologyOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03077698 | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | terminated | Phase 2 | 25 | Xenetic Biosciences, Inc.INDUSTRY | 1 | Jun 7, 2022 | clinicaltrials |
| NCT04230954 | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | terminated | Phase 2 | 5 | University of South AlabamaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT04150562 | Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | May 17, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT02913131 | Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies | terminated | Phase 1 / Phase 2 | 23 | Rahul AggarwalOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02945813 | SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy | terminated | Phase 2 | 112 | Swiss Cancer InstituteOTHER | 3 | Apr 14, 2022 | clinicaltrials |
| NCT02349386 | Maintaining Suppression of Testosterone With Transdermal Estradiol Gel(MASTERS) | terminated | Phase 2 | 34 | BHR Pharma, LLCINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03334409 | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 5 | Academic and Community Cancer Research UnitedOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | terminated | Phase 2 | 1 | NanOlogy, LLCINDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02362451 | Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Mar 18, 2022 | clinicaltrials |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | terminated | Phase 2 | 8 | TC BiopharmINDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01650285 | Cabazitaxel and Radiation For Patients With Prostate Cancer | terminated | Phase 2 | 5 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01650350 | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer | terminated | Phase 2 | 7 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT03549650 | Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms | terminated | Phase 2 | 3 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01126749 | Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 1 / Phase 2 | 92 | Eisai Inc.INDUSTRY | 6 | Feb 28, 2022 | clinicaltrials |
| NCT03441464 | Feasibility of the LUM Imaging System for Detection of Prostate Cancer | terminated | Phase 1 / Phase 2 | 9 | Lumicell, Inc.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT00594620 | Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy | terminated | Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03029611 | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03689582 | Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer | terminated | Phase 2 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01093066 | Prospective Multicentric Evaluation of a Bladder Preservation Strategy(ReChiVe) | terminated | Phase 2 | 77 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT03287050 | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma | terminated | Phase 2 | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | terminated | Phase 2 | 3 | MorphotekINDUSTRY | 2 | Dec 8, 2021 | clinicaltrials |
| NCT02648919 | Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer | terminated | Phase 2 | 6 | University of HawaiiOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | terminated | Phase 2 | 13 | BeiGeneINDUSTRY | 4 | Nov 17, 2021 | clinicaltrials |
| NCT01312389 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03342417 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | terminated | Phase 2 | 5 | ExcellaBio LLCINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT00900562 | Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy | terminated | Phase 2 | 19 | PharmaMarINDUSTRY | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | terminated | Phase 1 / Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT02792192 | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants | terminated | Phase 1 / Phase 2 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03886493 | Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer | terminated | Phase 2 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | University of WashingtonOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02959554 | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control(NIVOSWITCH) | terminated | Phase 2 | 49 | AIO-Studien-gGmbHOTHER | 2 | Sep 8, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | terminated | Phase 2 | 7 | Johannes Gutenberg University MainzOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT03545165 | 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC | terminated | Phase 1 / Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT01649180 | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma(PrE0801) | terminated | Phase 2 | 3 | PrECOG, LLC.OTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02985021 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | terminated | Phase 2 | 2 | Seattle Institute for Biomedical and Clinical ResearchOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy | terminated | Phase 2 | 140 | Latin American Cooperative Oncology GroupOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence | terminated | Phase 2 | 12 | Agenus Inc.INDUSTRY | 2 | Jun 3, 2021 | clinicaltrials |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT00582205 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma | terminated | Phase 2 | 21 | University of OklahomaOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT02055690 | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer(PAZOFOS) | terminated | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT02805894 | NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma | terminated | Phase 1 / Phase 2 | 5 | NanobiotixINDUSTRY | 1 | May 10, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 21, 2022source: clinicaltrials